Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30070812 | 0.87 | ELANE (0.49) | LMNASMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL14330483 | 0.87 | ELANE (0.49) | LMNASMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL2290756 | 0.85 | ALDH1A1 (0.61) | LMNAALDH1A1KDM4EMAPTHTT | |
| SCHEMBL14648839 | 0.84 | LMNA (0.58) | LMNASMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL31444062 | 0.84 | PTPN1 (0.48) | LMNASMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL4127583 | 0.84 | PTPN1 (0.55) | LMNASMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL3340831 | 0.84 | LMNA (0.77) | LMNASMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL2290004 | 0.84 | SLC6A3 (0.56) | LMNASMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL27891961 | 0.84 | CLCN2 (0.47) | LMNASMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL5722057 | 0.84 | MAPT (0.59) | LMNASMN1; SMN2KDM4EMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108497-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICALC., LTD. (JP) | 2026-04-23 | — | — | US | disclosed |
| US-20240148699-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
| US-20220265613-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-08-25 | — | — | US | disclosed |
| US-20200078340-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-03-12 | — | — | US | disclosed |
| US-20190070151-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-03-07 | — | — | US | disclosed |
| US-RE46792-E1 | Oxazole compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-04-17 | — | — | US | disclosed |
| US-20170216260-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| EP-1954684-B1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMA CO LTD (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-20140100226-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-04-10 | — | — | US | disclosed |
| US-8637559-B2 | Oxazole compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-28 | — | — | US | disclosed |
| EP-1426365-B1 | 3-PHENOXY-4-PYRIDAZINOL DERIVATIVE AND HERBICIDE COMPOSITION CONTAINING THE SAME | SANKYO AGRO CO LTD (JP) | 2009-07-15 | — | — | EP | disclosed |
| US-20090156646-A1 | PYRIDYLPHENOL COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1921066-A1 | PYRIDYLPHENOL COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-05-14 | — | — | EP | disclosed |
| EP-1879886-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1809280-A2 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| CN-1871228-A | A manufacturing process of isoflavan or isoflavene derivatives | BICBIO CO LTD (KR) | 2006-11-29 | — | — | CN | disclosed |
| WO-2006119146-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006044825-A2 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20050037925-A1 | 3-phenoxy-4-pyridazinol derivatives and herbicide composition containing the same | SANKYO AGRO COMPANY, LIMITED (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1426365-A1 | 3-PHENOXY-4-PYRIDAZINOL DERIVATIVE AND HERBICIDE COMPOSITION CONTAINING THE SAME | Sankyo Agro Company, Limited (JP) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216260-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | LMNA 3948/4885SMN1; SMN2 3069/4885ALDH1A1 234/4885 |
| US-20140100226-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | LMNA 3948/4885SMN1; SMN2 3069/4885ALDH1A1 234/4885 |
| US-20240148699-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | LMNA 3948/4885SMN1; SMN2 3069/4885ALDH1A1 234/4885 |
| US-20260108497-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE7B, PDE4B, PDE1B | LMNA 3066/4885SMN1; SMN2 2148/4885ALDH1A1 923/4885 |
| US-20090156646-A1 | PYRIDYLPHENOL COMPOUND AND USE THEREOF | GNRHR, PGR, MC1R | LMNA 448/4885SMN1; SMN2 2346/4885ALDH1A1 3446/4885 |
| US-20200078340-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | LMNA 3948/4885SMN1; SMN2 3069/4885ALDH1A1 234/4885 |
| US-20220265613-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | LMNA 3950/4885SMN1; SMN2 3357/4885ALDH1A1 248/4885 |
| US-20190070151-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | LMNA 3948/4885SMN1; SMN2 3069/4885ALDH1A1 234/4885 |
| US-20050037925-A1 | 3-phenoxy-4-pyridazinol derivatives and herbicide composition containing the same | CBR3, DDT, CHRM2 | LMNA 3977/4885SMN1; SMN2 3931/4885ALDH1A1 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.